Animal studies with bisacodyl have failed to reveal evidence of teratogenicity or fetotoxicity. At doses 70 times the maximum recommended human dose, there is evidence of decreased litter survival at weaning. Bisacodyl tablets have been used during human pregnancy without evidence of uterine relaxation. Due to the minimal absorption of bisacodyl, fetal risk is considered low.

Bisacodyl-PEG-ELS has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Bisacodyl-PEG-ELS is recommended for use during pregnancy when there are no alternatives and the potential benefits outweigh the potential risks.

See references

There are no data on the excretion of bisacodyl-PEG-ELS into human milk. The manufacturer recommends caution when bisacodyl-PEG-ELS is administered to nursing women.

See references